Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials is a research paper published in PLoS Medicine (2020). On theSindex it has a DataRank of 0. It has been cited 14 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institute of Allergy and Infectious Diseases
Grant: AI068614
National Institute of Allergy and Infectious Diseases
Grant: AI068618
National Institute of Allergy and Infectious Diseases
Grant: AI068635
National Institute of Allergy and Infectious Diseases
Grant: AI069412
National Institute of Allergy and Infectious Diseases
Grant: AI069453
National Institute of Allergy and Infectious Diseases
Grant: AI069519
National Institute of Allergy and Infectious Diseases
Grant: AI069469
National Institute of Allergy and Infectious Diseases
Grant: AI069422
Bill and Melinda Gates Foundation
Grant: OPP1110792
National Institute of Allergy and Infectious Diseases
Grant: AI108568
Bill and Melinda Gates Foundation
Grant: OPP1110830
National Institutes of Health
Grant: 3UM1AI108568-11S1
The Military HIV Research Program (MHRP) Clinical Trial Unit
National Institutes of Health
Grant: 3UM1AI068635-17S4
CoVPN 3001 - A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults.
National Institutes of Health
Grant: 2UM1AI069412-08
Harvard/Boston/Providence Clinical Trials Unit (Harvard/B/P CTU)
National Institutes of Health
Grant: 3UM1AI068614-15S2
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
National Institutes of Health
Grant: 5UM1AI069519-16
HIV/AIDS Clinical Trials Units University of Cape Town CTU 2020 to 2027
National Institutes of Health
Grant: 5UM1AI069469-10
CAPRISA Clinical Trials Unit for AIDS/Tuberculosis Prevention and Treatment
National Institutes of Health
Grant: 5UM1AI069422-13
South African Medical Research Council Clinical Trials Unit (MRC CTU)
National Institutes of Health
Grant: 3UM1AI068618-16S1
HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3
National Institutes of Health
Grant: 4UM1AI069453-07
Soweto Clinical Trials Unit
NIAID NIH HHS
Grant: UM1 AI069423
NIMH NIH HHS
Grant: R21 MH083308
NIAID NIH HHS
Grant: UM1 AI069412
NIAID NIH HHS
Grant: UM1 AI069481
NIAID NIH HHS
Grant: UM1 AI068614
NIAID NIH HHS
Grant: UM1 AI068618
NIAID NIH HHS
Grant: UM1 AI069453
NIAID NIH HHS
Grant: UM1 AI068635
NIAID NIH HHS
Grant: P30 AI060354
NIAID NIH HHS
Grant: UM1 AI069519
NIAID NIH HHS
Grant: U01 AI069412
NIAID NIH HHS
Grant: UM1 AI069422
NIAID NIH HHS
Grant: UM1 AI108568
FWCI
0.63
Citation Percentile
0.6%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals